Intensity Therapeutics Resumes Enrollment in Phase 3 Sarcoma Trial After FDA-Reviewed Protocol Amendment

Intensity Therapeutics is moving two paused oncology trials back into active enrollment, a sequence that puts its protocol amendment and site activation processes under direct scrutiny from clinical operations and regulatory teams watching how resource-constrained biotechs manage trial continuity. The company's $9.5 million cash position as of June 30, 2026 remains the binding constraint on how quickly either program can scale.

The INVINCIBLE-3 Phase 3 study, an open-label, randomized trial comparing INT230-6 monotherapy against standard-of-care in second- and third-line soft tissue sarcoma, was paused in March 2025 after enrolling 21 patients, when funding constraints forced Intensity to halt new site activations. During the pause, the company maintained pharmacovigilance, database integrity, and patient treatment obligations through its CRO network at reduced cost, while collecting investigator and key opinion leader feedback that informed protocol revisions. The FDA has reviewed the amended protocol, which will govern all new patient enrollment; EU site documentation is in progress. Enrollment and site activation rates are explicitly tied to available funding.

The INVINCIBLE-4 Phase 2 study in early-stage, operable triple negative breast cancer followed a different regulatory path. Enrollment paused in September 2025 after localized skin irritation near tumor sites prompted a dosing regimen review for Cohort A patients receiving INT230-6 presurgically. A protocol amendment lowering the drug volume-to-tumor volume ratio and reducing to a single injection was approved by Swissmedic and the Swiss Ethics Committee in March 2026. Patient treatment restarted in July 2026, and the company opened its first French site in August 2026 following EU submission of the modified protocol. Enrollment completion is targeted for end of 2027.

Preliminary data from the first 14 INVINCIBLE-4 patients, seven per cohort, show a 71% pathological complete response rate in the INT230-6 arm versus 42% in the standard-of-care-only cohort, alongside a 44% reduction in grade 3 adverse events in Cohort A. For clinical operations leads, those early safety signals directly informed the protocol amendment strategy and will be central to any future regulatory submissions.

For QA and regulatory leads benchmarking trial resumption workflows, the INVINCIBLE-3 sequence illustrates a specific compliance posture: maintaining pharmacovigilance and database integrity through a funding-driven pause, then implementing an FDA-reviewed amendment before reopening enrollment rather than resuming under the original protocol.

The pace of site activations across both programs will serve as the measurable indicator of whether Intensity's increased business development activities translate into the funding needed to sustain trial momentum through planned enrollment completion.

Source: Intensity Therapeutics, Inc. via PR Newswire, August 11, 2026. Management conference call held at 8:00 a.m. Eastern time; archived webcast available for replay.